Portal Vein Doppler Velocimetry as a Non-Invasive Tool for Assessing Liver Fibrosis in Hepatic Steatosis: A Comparative Study from Nnewi, Nigeria

Background: Hepatic steatosis is a major global health burden, often progressing to fibrosis, cirrhosis, and hepatocellular carcinoma. Liver biopsy remains the gold standard for fibrosis assessment, but its invasiveness limits its widespread use. Portal vein Doppler velocimetry and Serum biomarkers, such as the Aspartate Aminotransferase to Platelet Ratio Index (APRI), which provides biochemical insight, offer a non-invasive alternative for detecting hemodynamic changes associated with fibrosis.
Objective: To evaluate the correlation between portal vein Doppler velocimetry parameters and serum biomarkers of liver fibrosis in patients with hepatic steatosis, compared with apparently healthy controls in Nnewi, Nigeria.
Methods: A comparative cross-sectional study of 180 participants (90 with hepatic steatosis, 90 healthy controls) was conducted at Nnamdi Azikiwe University Teaching Hospital, Nnewi. Doppler parameters, including Peak Systolic Velocity (PSV), End Diastolic Velocity (EDV), and Portal Vein Pulsatility Index (PVPI), were measured. Serum biomarkers (AST, platelet count, APRI score) were analysed.
Results: Hepatic steatosis patients showed increased portal vein diameter (1.7 mm; 95% CI: 1.39–2.01) and PVPI (0.10; 95% CI: 0.081–0.119), with reduced PSV (−4.9 cm/s; 95% CI: −7.07 to −2.73) and EDV (−2.3 cm/s; 95% CI: −3.28 to −1.32) (p < 0.001). PSV decreased and PVPI increased with steatosis severity (p = 0.002 and p < 0.001). AST and APRI were higher, while platelet counts were lower (p < 0.001). PSV correlated inversely with APRI (r = −0.243, p = 0.022).
Conclusion: Portal vein Doppler velocimetry demonstrates significant alterations in hepatic steatosis and correlates with serum biomarkers of fibrosis. It represents a promising, cost-effective, non-invasive tool for fibrosis assessment in resource-limited settings.

Hepatic steatosis, Portal vein Doppler, Liver fibrosis, APRI score, Non-invasive diagnostics.

1. Brant WE. Core Curriculum: Ultrasound. 1st ed. Philadelphia: Lippincott Williams & Wilkins; 2001. [Google Scholar] [Crossref]

2. Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and prevention of hepatic steatosis. Gastroenterol Hepatol. 2015;11(3):1–75. [Google Scholar] [Crossref]

3. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276. [Google Scholar] [Crossref]

4. Paruk IM, Pirie FJ, Motala AA. Non-alcoholic fatty liver disease in Africa: a hidden danger. Glob Health Epidemiol Genom. 2019;4:e3. [Google Scholar] [Crossref]

5. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res. 2009;50(Suppl):S412–S416. [Google Scholar] [Crossref]

6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline. Hepatology. 2012;55(6):2005–2023. [Google Scholar] [Crossref]

7. Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome. J Gastroenterol Hepatol. 2013;28(4):664–670. [Google Scholar] [Crossref]

8. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2009;103(2):71–83. [Google Scholar] [Crossref]

9. Graham RC, Burke A, Stettler N. Ethnic and sex differences in NAFLD association with metabolic syndrome. J Pediatr Gastroenterol Nutr. 2009;49(4):442–449. [Google Scholar] [Crossref]

10. Ekhorse EA. The prevalence of non-alcoholic fatty liver disease among obese and non-obese patients with metabolic risk factors in National Hospital Abuja. 2015. [Google Scholar] [Crossref]

11. Chukwurah NS, Okonkwo UC, Ihekwaba AE. Comparative analysis of metabolic syndrome indices in NAFLD patients. Asian J Med Sci. 2019;10(2):40–45. [Google Scholar] [Crossref]

12. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends and prevention. 2017. [Google Scholar] [Crossref]

13. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of NAFLD. Hepatology. 2016;64(1):73–84. [Google Scholar] [Crossref]

14. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. Prevalence and incidence of NAFLD worldwide. Lancet Gastroenterol Hepatol. 2022;7:851–861. [Google Scholar] [Crossref]

15. Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. Radiographics. 2006;26(6):1637–1653. [Google Scholar] [Crossref]

16. Odenigbo CU, Oguejiofor OC, Ezejiofor OI, Jisieike-Onuigbo NN, Nwaneli CU, Umeh EO, et al. NAFLD among adults using ultrasound. Orient J Med. 2020;32(3–4):67–75. [Google Scholar] [Crossref]

17. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516–537. [Google Scholar] [Crossref]

18. Owen C, Meyers P, Sanchez D. Sonographic evaluation of the portal and hepatic systems. J Diagn Med Sonogr. 2006;22(5):317–328. [Google Scholar] [Crossref]

19. Seipalla GE, Nurahmi N, Samad IA. Liver fibrosis analysis with APRI and FIB-4 index in NAFLD. Indones J Clin Pathol Med Lab. 2019;26(2):158–161. [Google Scholar] [Crossref]

20. Ali R, Cusi K. New diagnostic and treatment approaches in NAFLD. Ann Med. 2009;41(4):265–278. [Google Scholar] [Crossref]

21. Liao XH, Cao X, Liu J, Xie XH, Sun YH, Zhong BH. Prevalence of fatty liver in Guangzhou. World J Gastroenterol. 2013;19(32):5334–5339. [Google Scholar] [Crossref]

22. Gabkwet AE, Igoh EO, Gwom PM, Taiwo FY, Salaam AJ, Danjem SM, et al. Evaluation of fatty liver disease in Nigeria using ultrasound. Int J Adv Med. 2021;8(8):1020–1025. [Google Scholar] [Crossref]

23. Janiec DJ, Jacobson ER, Freeth A, Spaulding L, et al. Histologic variation in NAFLD biopsies. Obes Surg. 2005;15(4):497–501. [Google Scholar] [Crossref]

24. Hannah WN, Harrison SA. Noninvasive imaging methods for NAFLD severity. Hepatology. 2016;64:2234–2243. [Google Scholar] [Crossref]

25. AlShaalan R, Aljiffry M, Al-Busafi S, Metrakos P, et al. Noninvasive diagnosis of hepatic steatosis. Saudi J Gastroenterol. 2015;21(2):64–70. [Google Scholar] [Crossref]

26. Mayo R, Crespo J, Martínez-Arranz I, Banales JM, Arias M, Mincholé I, et al. Metabolomic-based test for NASH diagnosis. Hepatol Commun. 2018;2:807–820. [Google Scholar] [Crossref]

27. Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for liver steatosis diagnosis. World J Gastroenterol. 2019;25(40):6053–6062. [Google Scholar] [Crossref]

28. Kolhe KM, Amarapurkar A, Parikh P, Chaubal A, Chauhan S, Khairnar H, et al. APRI accuracy in NAFLD fibrosis. BMJ Open Gastroenterol. 2019;6(1):e000288. [Google Scholar] [Crossref]

29. Baikpour M, Ozturk A, Dhyani M, Mercaldo ND, Pierce TT, et al. Portal venous pulsatility index: a novel biomarker for high-risk NAFLD. AJR Am J Roentgenol. 2020;214(4):786–791. [Google Scholar] [Crossref]

30. Gbande P, Soumah A, Balde AA, Tchaou M, Sonhaye L, et al. Doppler ultrasound assessment of hepatic hemodynamics in steatosis. Egypt J Radiol Nucl Med. 2025;56:198. [Google Scholar] [Crossref]

31. Aydin MM, Akcali KC. Liver fibrosis. Turk J Gastroenterol. 2018;29(1):14–21. [Google Scholar] [Crossref]

32. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Ávila F. APRI for noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008;7(4):350–357. [Google Scholar] [Crossref]

33. Caldwell S, Argo C. Natural history of NAFLD. Dig Dis. 2010;28(1):162–168. [Google Scholar] [Crossref]

34. Aytoon AA, Gad Allah ANA, Faisal A. Prediction of liver disease using Doppler vs biopsy in hepatitis C. Res Rep Focus Ultrasound. 2014;2:1–11. [Google Scholar] [Crossref]